GREENWICH, Conn.--(BUSINESS WIRE)--Aptuit Inc. announced today the launch of a new program to accelerate early stage drug development. Aptuit INDiGO™ is a fully customizable program that offers an accelerated track from preclinical candidate selection to regulatory submission (IND, CTA) to support Phase 1 Clinical Trials. Aptuit’s approach streamlines the pre-Phase 1 process by reducing the typical hand-off delays and development obstacles that slow a molecule’s progress in the traditional drug development model.
